<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of the present study was to investigate the relevance of monitoring metabolic reduction evaluated by (18) F-fluorodeoxyglucose ((18) F-FDG) PET/CT in relapsed or refractory patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) and mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) who received bendamustine </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted a phantom study of <z:chebi fb="0" ids="36939">18F</z:chebi>-FDG PET/CT to ensure quality control for performing a multicenter clinical study </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed 49 patients with relapsed or refractory FL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> who received bendamustine (120 mg/m(2)) on days 1-2 of a 21-day cycle for up to six cycles as a licensing phase II study </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="36939">18F</z:chebi>-FDG PET/CT scans were acquired before the first and after the last cycle </plain></SENT>
<SENT sid="4" pm="."><plain>In a total of 175 target lesions, the maximum perpendicular diameter (Max <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>), minimum <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> (Min <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>), sum of the products of the Max <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> (SPD), maximum standardized uptake value (SUVmax), and the percentage reduction rates of Max <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> (%Max <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>), SPD (%SPD) and SUVmax (%SUVmax) were evaluated for the response to treatment </plain></SENT>
<SENT sid="5" pm="."><plain>The therapeutic response was assessed after the last cycle of treatment according to the revised response criteria for malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (revised RC) </plain></SENT>
<SENT sid="6" pm="."><plain>We evaluated 134 lesions in 39 patients (76%) achieving complete response (CR) and 41 lesions in 10 patients (24%) not achieving CR </plain></SENT>
<SENT sid="7" pm="."><plain>The Max <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>, Min <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>, SPD and SUVmax of the lesions after the last cycle were significantly higher in patients with non-CR than in patients with CR </plain></SENT>
<SENT sid="8" pm="."><plain>The %<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>, %SPD and %SUVmax of the lesions were significantly greater in patients with CR than in patients with non-CR (P &lt; 0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>Metabolic reduction was observed in <z:hpo ids='HP_0000001'>all</z:hpo> target lesions of relapsed or refractory patients with FL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> who achieved CR after bendamustine therapy </plain></SENT>
</text></document>